Everest Medicines erhält Zulassung für VELSIPITY in China
I'm PortAI, I can summarize articles.
Everest Medicines Ltd. has received approval from the National Medical Products Administration (NMPA) in China for VELSIPITY (etrasimod arginine tablets) to treat adults with moderate to severe active ulcerative colitis who have inadequate response, loss of response, or intolerance to conventional therapies or biological agents. The company is preparing for the product launch in China and plans to include it in the national reimbursement list.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments